GP2
Global Parkinson's Genetics Program | Michael J Fox Foundation
This large-scale international dataset provides access to genomic data (primarily whole-genome genotyping and sequencing) from over 70,000 participants, including individuals with Parkinson's disease (PD) and related disorders, related individuals, and healthy controls, with a strong emphasis on genetic diversity. It is a critical resource for researchers investigating the genetic architecture of PD, identifying novel risk variants across diverse populations, exploring gene-environment interactions, and accelerating the development of genetically informed therapies.
GP2 (Global Parkinson’s Genetics Program) comprises a collection of independently led active and completed studies of Parkinson's disease with genetic data collection. Cohort contributors to GP2 are partners in its global mission to improve our understanding of Parkinson's disease and accelerate scientific breakthroughs.
Datasets
GP2
Data Collection Time Frame
2020 - Present
Participants
Current: 71,835
Target: 200,000
Geographical Coverage
International
Usage Examples
- Understanding global genetic variation and correlation with disease outcomes.
- Assessing potential precision medicine approaches (e.g., personalized risk prediction, prevention, treatment).
- Exploring genetic pathways to nominate targets and candidate biomarkers in context of global genetics.
- Researching factors contributing to wellness, resilience, and healthy aging.
- Evaluating pharmacogenetic research to prioritize and evaluate potential therapeutics or assess variability in drug response.
- Accelerating discoveries across a wide range of diseases (e.g., cancer, cardiovascular disease, diabetes, neurological disorders).
Data Modalities
Genomics
- Whole Genome Sequencing (WGS)
- Genotyping Arrays
- Genomic Summary Statistics
- Structural Variant (SV) Data
- Gene Mutation Status
Biosamples
- Blood
- Saliva
Clinical Data
- Demographics
- Medical History
- Family History
- Clinical Assessments / Scales